Investment Thesis
Lunai Bioworks exhibits critical financial distress with negative stockholders' equity (-$13.5M), near-zero and collapsing revenue ($24.3K, -203.8% YoY), and negative operating cash flow (-$2.4M). The company cannot sustain operations or service $20.2M liabilities with current economics, presenting severe bankruptcy risk.
Strengths
- Minimal capital expenditure requirements reduce ongoing cash burn beyond operating losses
- Pharmaceutical sector positioning retains potential value if pipeline assets attract partnership or acquisition
- Small asset base could facilitate orderly restructuring or strategic transaction
Risks
- Negative stockholders' equity of -$13.5M indicates technical insolvency
- Revenue collapse of 203.8% YoY with near-zero topline suggests complete operational failure
- Operating cash outflow of -$2.4M unsustainable; current cash of $491.6K provides only ~3 months runway
- Critically low liquidity (0.03x current ratio) with $20.2M total liabilities; inability to meet short-term obligations
- Negative interest coverage (-6.8x) indicates inability to service debt from operations; no Form 4 insider activity suggests management loss of confidence
Key Metrics to Watch
- Monthly cash burn rate and remaining runway before insolvency
- Any revenue stabilization or partnership/licensing deal announcements
- Stockholders' equity trajectory and capital raise activity
- Changes in total liabilities indicating restructuring or debt repayment
Financial Metrics
Revenue
24.3K
Net Income
1.0M
EPS (Diluted)
$0.04
Free Cash Flow
-2.4M
Total Assets
6.7M
Cash
491.6K
Profitability Ratios
Gross Margin
154.2%
Operating Margin
-21,107.1%
Net Margin
4,193.7%
ROE
N/A
ROA
15.3%
FCF Margin
-9,959.9%
Balance Sheet & Liquidity
Current Ratio
0.03x
Quick Ratio
0.03x
Debt/Equity
N/A
Debt/Assets
303.2%
Interest Coverage
-6.77x
Long-term Debt
540.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T17:06:27.169528 |
Data as of: 2025-12-31 |
Powered by Claude AI